Biogen Idec Ma Inc.

The General Hospital Corporation

Veronique Bailly

Joseph V Bonventre

Alexey Alexandrovich Lugovskoy

Jeffrey L Browning

Ellen A Garber

Paul David Rennert

Scott Glaser

Christilyn Graff

Graham K Farrington

Xinzhong Wang

Patricia McCoon

LIGHT-targeting molecules (e.g., LIGHT fusion molecules), anti-HER2 antibody molecules, compositions, e.g., pharmaceutical compositions thereof, are disclosed. Methods of using these molecules to treat, prevent and/or diagnose hyperproliferative, e.g., neoplastic, diseases or conditions, including, but not limited to, cancer and metastasis are also provided.

Light targeting molecules and uses thereof

Compositions and methods for treating Th2- and ThI-mediated disease are provided.

KIM-1 antibodies for treatment of TH2-mediated conditions

Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.

Methods of decreasing tumor volume and reducing tumor burden using TNF-receptor-coupling agents

Receptor coupling agents and compositions thereof

Disclosed are antibodies that inhibit proteolytic release of a soluble KIM-1 polypeptide from KIM-1 expressing cells. Also disclosed are methods of using the antibodies to inhibit shedding of the KIM-1 polypeptide.

Molecules and methods for inhibiting shedding of KIM-1

Growing community of inventors

Boxborough, MA, United States of America

Veronique Bailly